The application period for 2026-27 B/C/C volunteer leadership roles is open now through April 30 | LEARN MORE

The DO

The craze behind weight-loss injectables

By The DO Staff

09.22.23

In 2012, Novo Nordisk synthesized a compound called semaglutide in an effort to increase the half-life of its counterpart drug liraglutide. These glucagon-like-peptide-1 receptor agonists, originally formulated for patients with Type 2 diabetes, work by promoting the release of insulin to decrease glucose levels.